Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2156-2159, 2005; 10.1373/clinchem.2005.048686
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bernacki, S. H.
Right arrow Articles by Stenzel, T. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernacki, S. H.
Right arrow Articles by Stenzel, T. T.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2005;51:2156-2159.)
© 2005 American Association for Clinical Chemistry, Inc.

Technical Briefs

Characterization of Publicly Available Lymphoblastoid Cell Lines for Disease-Associated Mutations in 11 Genes

Susan H. Bernacki1,1, Jeanne C. Beck2, Kasinathan Muralidharan3, Frederick V. Schaefer4, Antony E. Shrimpton5, Kristy L. Richie6, Barbara C. Levin6, Genevieve Pont-Kingdon7 and Timothy T. Stenzel1,a

1 Department of Pathology, Duke University Medical Center, Durham, NC; 2 Coriell Cell Repositories, Coriell Institute for Medical Research, Camden, NJ; 3 Department of Human Genetics, Emory University School of Medicine, Atlanta, GA; 4 Center for Genetic Testing at Saint Francis, Tulsa, OK; 5 Department of Pathology, State University of New York Upstate Medical University, Syracuse, NY; 6 DNA Technologies Group, National Institute of Standards and Technology, Gaithersburg, MD; 7 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT;

aaddress correspondence to this author at: Abbott Molecular, 1300 E. Touhy Ave., Des Plaines, IL 60016; fax 224-361-7054, e-mail timothy.stenzel@abbott.com

The first 300 words of the full text of this article appear below.

Clinical genetic testing laboratories offer tests for >800 conditions (1) and need both positive and negative genetic control materials for proficiency evaluation, quality control, and test development/validation. Few such materials are available(2)(3)(4)(5). Genetic material, generally DNA, can be purified from Epstein–Barr virus (EBV)-transformed lymphocyte cell lines. The resulting preparations closely resemble DNA purified from patient samples and often are appropriate controls for clinical genetic testing applications. The National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository(6) and the National Institute on Aging (NIA) Aging Cell Repository(7) house thousands of EBV-transformed cell lines, but mutations have been described in only ~600 of these.

We screened 13 cell lines from the NIGMS Repository for medically important mutations in 11 different genes: CFTR, F5, F2, MTHFR, HFE, GJB2 (connexin 26), FMR1 (fragile X), HBA1/HBA2 ({alpha}-thalassemia), FGFR3, HD, and HbS/HbC. Six of the cell lines had previously been shown to carry 1 or more mutations in at least one of these genes, and 7 were derived from apparently healthy individuals with no known mutations. Some cell lines were subsequently developed for use as clinically validated positive controls for molecular genetic testing or were used as negative control materials [see accompanying article by Bernacki et al (8), in this issue].

DNA was extracted according to the Puregene protocol (Gentra Systems, Inc.). Selected mutations were analyzed by standard molecular diagnostic techniques at the Duke Molecular Diagnostics Laboratory and/or at other CLIA-certified clinical testing facilities where indicated. The 11 diseases characterized, the specific mutations analyzed, and the general methods used are listed below. The OMIM numbers (9) are listed in Table 1 .


View this table:
[in this window]
[in a new window]
  		Table 1. Mutations detected in EBV-transformed blood lymphocyte . . . [Full Text of this Article]

Cystic Fibrosis (CFTR; ABCC7).
Factor V Leiden thrombophilia (FVL; F5), prothrombin thrombophilia (F2), and methylenetetrahydrofolate reductase (MTHFR) deficiency.
Hereditary hemochromatosis (HFE).
Nonsyndromic hereditary hearing loss/connexin 26 (GJB2).
Fragile X.
{alpha}-Thalassemia.
Nonsyndromic craniosynostosis (Muenke syndrome; FGFR3)
Huntington disease (HD).
Sickle cell/hemoglobin C disease (HbS/HbC).



The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. H. Bernacki, J. C. Beck, A. K. Stankovic, L. O. Williams, J. Amos, K. Snow-Bailey, D. H. Farkas, M. J. Friez, F. M. Hantash, K. J. Matteson, et al.
Genetically Characterized Positive Control Cell Lines Derived from Residual Clinical Blood Samples
Clin. Chem., November 1, 2005; 51(11): 2013 - 2024.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.